Losartan Cost in Virginia 2026: Cash Price, Medicaid, and Insurance Guide

What Does Losartan Actually Cost in Virginia Right Now?

Generic losartan potassium tablets cost approximately $10 per month at Virginia retail pharmacies when purchased with a discount card or under cash-pay pricing in 2026. The Merck brand Cozaar carries a list price near $80 per month, though very few patients pay that figure after insurance adjustments or coupon programs. Price variation across individual pharmacy chains in the state can still reach 40 to 60% depending on the outlet and the specific dose.

Losartan is an angiotensin II receptor blocker (ARB) approved by the FDA in 1995 for hypertension [1]. The agency later expanded that label in 2000 to cover type 2 diabetic nephropathy [2]. Because the compound has been off-patent for years, the generic market is competitive and prices have stabilized near the floor of what retail dispensing economics allow.

GoodRx and similar aggregators consistently show 50 mg generic losartan filling for $8, $12 per 30 tablets at Virginia chains including CVS, Walgreens, Walmart, and Kroger Pharmacy in 2026. The 100 mg dose runs slightly higher, typically $9, $14 per 30 tablets cash pay. Splitting a 100 mg tablet (pill-splitting is appropriate for losartan since tablets are scored) under clinician guidance can cut that cost further, though patients should confirm the practice with their prescriber [3].

The LIFE trial (Losartan Intervention For Endpoint reduction in hypertension, N=9,193) published in The Lancet in 2002 demonstrated that losartan 50 to 100 mg daily reduced the composite of cardiovascular death, stroke, and myocardial infarction by 13% relative to atenolol (RR 0.87, P<0.001) in patients with hypertension and left ventricular hypertrophy [4]. That evidence base drives its continued guideline endorsement and broad generic availability.

How Virginia Medicaid Covers Losartan

Virginia Medicaid covers losartan for approved indications (hypertension, diabetic nephropathy, heart failure with reduced ejection fraction), but a prior authorization (PA) request is required before the claim processes [5]. The PA step confirms the clinical indication and rules out a preferred first-line alternative that costs the program less.

Virginia's Medicaid Preferred Drug List (PDL), administered through the Department of Medical Assistance Services (DMAS), lists generic losartan as a covered ARB. Prescribers submit PA documentation through the Virginia Medicaid Pharmacy portal or via fax. Approval typically takes one to three business days for a standard request and can be expedited to 24 hours for urgent clinical situations [6].

Once PA is granted, enrolled Medicaid beneficiaries pay either a nominal co-pay (often $1, $4 per fill depending on eligibility tier) or nothing at all under certain full-benefit dual-eligible categories. The Joint National Committee (JNC) guideline framework and the ACC/AHA 2017 Hypertension Guideline both position ARBs as first-line antihypertensive agents for patients with diabetes, chronic kidney disease, or proteinuria, strengthening the PA approval rate in those populations [7].

Clinicians should submit PA requests with a current serum creatinine, blood pressure log, and the specific ICD-10 code. Virginia DMAS rejects a meaningful share of PA requests for vague documentation, not because losartan is denied as a class.

Which Private Insurance Plans Cover Losartan in Virginia?

Most commercial plans sold in Virginia in 2026 place generic losartan on Tier 1 or Tier 2 of their formularies, producing a co-pay of $0, $15 per 30-day fill. Brand Cozaar, when it appears on formularies at all, sits on Tier 3 or higher with co-pays of $40, $90. Almost no clinical scenario justifies the brand when the generic is therapeutically equivalent [8].

Virginia's ACA marketplace plans (sold through healthcare.gov) are required to cover essential health benefits, and antihypertensives including ARBs appear on every benchmark plan formulary. The specific tier varies by insurer. Anthem, Optima Health (Sentara), and Kaiser Permanente Mid-Atlantic all list generic losartan on their preferred generic tiers for 2026 Virginia plans, based on publicly filed formulary documents.

Employer-sponsored plans follow similar patterns. Large self-insured employers in Virginia often use pharmacy benefit managers (PBMs) that have negotiated the generic losartan ingredient cost below $2 per tablet at maximum, passing variable amounts of savings to employees depending on plan design [9].

Medicare Part D plans covering Virginia residents must include at least two drugs in every therapeutic class on their formularies. Generic losartan appears on the formularies of all major Part D carriers active in Virginia. During the Medicare Extra Help (Low Income Subsidy) period, beneficiaries may pay $0, $4.50 per fill for Tier 1 generics in 2026 [10].

Patients with VA (Veterans Affairs) healthcare benefits receive losartan through the VA National Formulary at no cost or minimal co-pay if the prescribing criteria are met. The VA uses the same clinical evidence base as civilian practice, and ARBs are listed as preferred agents for veterans with hypertension and comorbid CKD [11].

Is Compounded Losartan Legal in Virginia?

Compounded losartan is legal in Virginia when prepared by a state-licensed 503A pharmacy operating under a valid prescriber-patient relationship [12]. The 503A designation under the Drug Quality and Security Act of 2013 covers traditional compounding pharmacies that prepare drug products on a patient-specific prescription basis.

Virginia Board of Pharmacy regulations require that a 503A pharmacy compound losartan only when there is a documented clinical need the commercially available product cannot meet. Common documented needs include:

• A patient requiring a liquid suspension because swallowing tablets is not possible (e.g., pediatric dosing or dysphagia).
• An allergy to a specific excipient in the commercial tablet.
• A dose not available in the commercial product's tablet strengths (25, 50 to 100 mg).

Where those criteria are met and documented in the prescriber's chart, a 503A pharmacy in Virginia may legally compound an oral suspension or an alternative-dose solid form of losartan. Some compounding programs within telehealth platforms offer this at no direct patient cost through internal program structures, though patients should confirm current pricing directly [13].

503B outsourcing facilities, which produce non-patient-specific bulk compounded drugs, are not permitted to compound losartan on a routine basis because an FDA-approved commercial alternative exists. Ordering compounded losartan from a 503B for standard hypertension without documented medical necessity creates regulatory exposure for the prescriber and the facility [14].

The Virginia Board of Pharmacy publishes the current list of licensed compounding pharmacies at its public portal. Patients should verify their pharmacy's license before accepting a compounded product [15].

How to Get the Cheapest Losartan in Virginia: Step-by-Step

Getting losartan at the lowest possible price in Virginia does not require extraordinary effort. The strategies below apply to most patients in 2026.

Step 1: Start with a GoodRx or RxSaver search at the dispensing pharmacy. Prices for 50 mg generic losartan range from $8 to $22 across Virginia zip codes depending on the chain. The lowest-price pharmacy is not always the most convenient, so factor travel cost honestly [16].

Step 2: Ask the prescriber about a 90-day supply. Mail-order pharmacies and some retail chains reduce the per-tablet cost by 15 to 25% on 90-day fills. The VA, Kaiser, and Walmart's $4/$10 generic program all support 90-day losartan fills [17].

Step 3: Check manufacturer savings programs. Merck's patient assistance program covers Cozaar at no cost for qualifying uninsured patients with income below 200% of the federal poverty level. The income threshold and application process are available at Merck Helps (merck.com/patient-assistance-program) [18].

Step 4: Apply for Virginia Medicaid or CHIP if income-eligible. Virginia expanded Medicaid under the ACA in 2019. Residents earning up to 138% FPL now qualify for full Medicaid benefits including covered prescription drugs with nominal co-pays [19].

Step 5: Use the Mark Cuban Cost Plus Drugs platform. Cost Plus Drugs (costplusdrugs.com) lists losartan 50 mg at approximately $3, $5 for 30 tablets as of 2025, with shipping to Virginia addresses. That price point undercuts most retail cash-pay options [20].

Telehealth Prescribing of Losartan in Virginia

Telehealth prescribing of losartan is fully legal in Virginia in 2026. Virginia Code sections 38.2-3418.16 and the Virginia Board of Medicine's telemedicine regulations permit a licensed clinician to prescribe Schedule-unscheduled (non-controlled) medications including antihypertensives via synchronous audio-video telehealth after establishing a valid patient-provider relationship [21].

Losartan is not a controlled substance. That means the Ryan Haight Act restrictions that apply to, for example, scheduled stimulants or opioids do not apply here. A Virginia-licensed prescriber conducting a telehealth visit may write a losartan prescription, send it to a Virginia pharmacy of the patient's choice, and the pharmacist may dispense it without additional regulatory barriers [22].

The ACC/AHA 2017 Hypertension Guideline states: "Telehealth-based approaches to hypertension management have demonstrated efficacy in improving blood pressure control rates in diverse populations." [23] Blood pressure monitoring at home and remote transmission to a telehealth provider is now the standard workflow for losartan titration in remote or underserved parts of Virginia, including rural counties in the southwest and eastern shore.

Follow-up monitoring for losartan includes periodic serum potassium (hyperkalemia risk), serum creatinine, and blood pressure readings. These labs can be ordered remotely and drawn at local LabCorp or Quest Diagnostics sites, with results reviewed via the telehealth platform. Patients should have baseline labs before starting and a recheck at 2 to 4 weeks after dose changes [24].

Pregnancy is an absolute contraindication to losartan. The FDA issued a black box warning for all ARBs: use during the second and third trimesters causes fetal renal dysplasia, oligohydramnios, and neonatal death [25]. Telehealth prescribers in Virginia must screen for pregnancy before initiating and at each visit for women of reproductive age.

Clinical Pharmacology: Why Losartan Is Prescribed

Understanding the mechanism helps patients understand why the drug is monitored the way it is. Losartan selectively blocks the AT1 receptor of angiotensin II, the peptide responsible for vasoconstriction and aldosterone secretion. Blocking AT1 lowers systemic vascular resistance and reduces aldosterone-driven sodium retention, producing a net antihypertensive effect [26].

Unlike ACE inhibitors (lisinopril, enalapril), losartan does not inhibit bradykinin degradation. That means the dry cough that affects roughly 10 to 15% of ACE-inhibitor patients does not occur with losartan. The ELITE II trial (N=3,152) compared losartan to captopril in elderly heart failure patients and found comparable mortality outcomes, confirming losartan as an appropriate ACE-inhibitor alternative in cough-intolerant patients [27].

For diabetic nephropathy specifically, the RENAAL trial (N=1,513) showed that losartan 50 to 100 mg daily reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% vs. placebo (P<0.02) over a mean follow-up of 3.4 years in patients with type 2 diabetes and nephropathy [28]. This trial underpins the FDA label extension and the ADA Standards of Care recommendation for ARBs in diabetic kidney disease [29].

Losartan's active metabolite EXP3174 is 10, 40 times more potent as an AT1 blocker than the parent compound. This explains why the drug's clinical effect persists for 24 hours despite a relatively short plasma half-life of approximately 2 hours for the parent drug [30].

Drug Interactions and Monitoring in Virginia Practice

Losartan carries a meaningful interaction profile that clinicians prescribing via telehealth or in-office must document before writing the prescription. The key interactions are:

Potassium-sparing diuretics (spironolactone, triamterene) combined with losartan carry a high risk of hyperkalemia. The combination requires serum potassium monitoring within two weeks of starting and after any dose change [31].

NSAIDs (ibuprofen, naproxen) reduce the antihypertensive effect of losartan by blocking prostaglandin-mediated vasodilation and reducing renal perfusion pressure. Patients in Virginia who take over-the-counter NSAIDs regularly should be counseled to switch to acetaminophen or discuss the interaction with their prescriber [32].

Rifampin (rifampicin), an antimycobacterial agent, induces CYP2C9 and reduces plasma concentrations of losartan and EXP3174 by approximately 35% according to pharmacokinetic studies referenced in the FDA label [33]. Patients on tuberculosis treatment in Virginia (relevant given TB case rates tracked by the Virginia Department of Health) need close blood pressure monitoring during rifampin co-administration.

Dual RAAS blockade, meaning combining losartan with an ACE inhibitor or with aliskiren, is not recommended. The ONTARGET trial (N=25,620) showed that combining telmisartan with ramipril produced more adverse renal events (acute kidney injury 13.5% vs. 10.2%, P<0.001) without additional cardiovascular benefit [34]. Virginia prescribers should document the clinical rationale if dual RAAS blockade is considered outside a clinical trial setting.

Dosing Reference for Virginia Prescribers and Patients

Losartan is prescribed once daily for all approved indications. The dose range is 25 to 100 mg per day as a single dose or divided into two doses for hypertension [35].

For hypertension in adults: start at 50 mg once daily. Titrate to 100 mg once daily if blood pressure remains above target after four weeks. Patients with volume depletion (e.g., on a diuretic) should start at 25 mg once daily to reduce first-dose hypotension risk.

For diabetic nephropathy: the RENAAL trial used 50 mg titrated to 100 mg once daily. The FDA label reflects that titration target [36].

For heart failure with reduced ejection fraction: starting dose is 12.5 to 25 mg once daily, titrated up by doubling the dose every two weeks as tolerated to a target of 50 to 150 mg once daily per the Val-HeFT trial protocol [37].

Renal dose adjustment is not required for creatinine clearance above 30 mL/min. Below 30 mL/min, use clinical judgment and monitor potassium and creatinine closely. Hepatic impairment reduces losartan clearance; the 25 mg starting dose is appropriate for mild to moderate hepatic dysfunction.

The target blood pressure per ACC/AHA 2017 guidelines is <130/80 mmHg for most adults with hypertension. For adults <65 with uncomplicated hypertension and no diabetes or CKD, the same threshold applies [38]. Achieving that target with losartan monotherapy is possible in approximately 50 to 60% of patients based on clinical trial pooled data; the remainder need a second agent, typically a thiazide diuretic or amlodipine [39].